SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SCHWARTZ ALICE N

(Last)

(First)

(Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES

94547

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO RAD LABORATORIES INC [ BIO, BIOB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2012

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Bio-Rad A Common Stock								2,772,912	D
Bio-Rad A Common Stock								34,311	I	By Trust
Bio-Rad B Common Stock	12/03/2012		M		8,000⁽¹⁾	A	$36	489,436⁽²⁾	D
Bio-Rad B Common Stock	12/03/2012		M		7,608⁽¹⁾	A	$53.5	497,044	D
Bio-Rad B Common Stock	12/03/2012		M		8,227⁽¹⁾	A	$56.4	505,271	D
Bio-Rad B Common Stock	12/03/2012		M		8,413⁽¹⁾	A	$63	513,684	D
Bio-Rad B Common Stock	12/03/2012		M		4,000⁽¹⁾	A	$75	517,684	D
Bio-Rad B Common Stock	12/03/2012		M		3,000⁽¹⁾	A	$88.48	520,684	D
Bio-Rad B Common Stock	12/03/2012		M		2,000⁽¹⁾	A	$75.38	522,684	D
Bio-Rad B Common Stock	12/03/2012		M		1,000⁽¹⁾	A	$84.57	523,684	D
Bio-Rad B Common Stock	12/03/2012		F		24,014	D	$104.85	499,670	D
Bio-Rad B Common Stock	12/03/2012		G		720	D	$0	498,950	D
Bio-Rad B Common Stock								4,060,054	I	By Blue Raven Partners, L.P.⁽³⁾
Bio-Rad B Common Stock								41,176	I	By DANSA Partners Limited⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$36	12/03/2012		M			8,000	⁽⁵⁾	02/05/2013	Bio-Rad B Common Stock	8,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$53.5	12/03/2012		M			7,608	⁽⁶⁾	02/04/2014	Bio-Rad B Common Stock	7,608	$0	0	D
Non-Qualified Stock Option (right to buy)	$56.4	12/03/2012		M			8,227	⁽⁷⁾	02/09/2015	Bio-Rad B Common Stock	8,227	$0	0	D
Non-Qualified Stock Option (right to buy)	$63	12/03/2012		M			8,413	⁽⁸⁾	04/03/2016	Bio-Rad B Common Stock	8,413	$0	0	D
Non-Qualified Stock Option (right to buy)	$75	12/03/2012		M			4,000	⁽⁹⁾	08/01/2017	Bio-Rad B Common Stock	4,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$88.48	12/03/2012		M			3,000	⁽¹⁰⁾	06/11/2018	Bio-Rad B Common Stock	3,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$75.38	12/03/2012		M			2,000	⁽¹¹⁾	06/10/2019	Bio-Rad B Common Stock	2,000	$0	0	D
Non-Qualified Stock Option (right to buy)	$84.57	12/03/2012		M			1,000	⁽¹²⁾	09/08/2020	Bio-Rad B Common Stock	1,000	$0	0	D

Explanation of Responses:

1. The stock option exercise reported is the exercise of derivative securites acquired upon the death of the reporting person's spouse, David Schwartz, former Chairman of the Board of Bio-Rad Laboratories, Inc. and beneficial owner of more than 10% of the Company's Common Stock.

2. 1,002 unvested restricted stock Class B shares held by the reporting person's late spouse, David Schwartz, were forfeited as of the date of his death, April 1, 2012.

3. The shares are held by a limited partnership of which the reporting person is a limited and general partner.

4. The shares are held by a limited partnership of which the reporting person is a general partner.

5. The stock option became exercisable in five equal annual installments beginning on February 5, 2004.

6. The stock option became exercisable in five equal annual installments beginning on February 4, 2005.

7. The stock option became exercisable in five equal annual installments beginning on February 9, 2006.

8. The stock option became exercisable in five equal annual installments beginning on April 3, 2007

9. The stock option became exercisable in five equal annual installments beginning on August 1, 2008.

10. The stock option became exercisable in five equal annual installments beginning on June 11, 2009.

11. The stock option became exercisable in five equal annual installments beginning on June 10, 2010.

12. The stock option became exercisable in five equal annual installments beginning on September 8, 2011.

Remarks:

	Alice N. Schwartz	12/05/2012
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.